Skip to main content

Table 4 Most common any-grade (≥ 25% of patients) and grade 3/4 (≥ 5% of patients) TEAEs

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

 

Any grade

Grade 3/4

 

Standard risk

High riska

Standard risk

High riska

TEAE, n (%)

D-Vd (n = 137)

Vd (n = 136)

D-Vd (n = 40)

Vd (n = 34)

D-Vd (n = 137)

Vd (n = 136)

D-Vd (n = 40)

Vd (n = 34)

Hematologic

 Thrombocytopenia

85 (62)

58 (43)

24 (60)

16 (47)

65 (47)

45 (33)

19 (48)

12 (35)

 Anemia

45 (33)

41 (30)

7 (18)

14 (41)

25 (18)

23 (17)

4 (10)

6 (18)

 Neutropenia

29 (21)

16 (12)

9 (23)

3 (9)

21 (15)

6 (4)

6 (15)

2 (6)

 Lymphopenia

18 (13)

5 (4)

4 (10)

4 (12)

14 (10)

3 (2)

3 (8)

3 (9)

 Leukopenia

15 (11)

5 (4)

3 (8)

3 (9)

5 (4)

1 (1)

1 (3)

2 (6)

Nonhematologic

 Peripheral sensory neuropathy

67 (49)

50 (37)

22 (55)

13 (38)

4 (3)

8 (6)

2 (5)

4 (12)

 Upper respiratory tract infection

43 (31)

20 (15)

15 (38)

8 (24)

1 (1)

0

3 (8)

1 (3)

 Diarrhea

42 (31)

35 (26)

11 (28)

6 (18)

6 (4)

2 (2)

1 (3)

0

 Cough

40 (29)

19 (14)

9 (23)

4 (12)

0

0

0

0

 Fatigue

25 (18)

40 (29)

17 (43)

8 (24)

6 (4)

5 (4)

2 (5)

1 (3)

 Back pain

24 (18)

15 (11)

13 (33)

1 (3)

3 (2)

0

1 (3)

0

 Insomnia

22 (16)

20 (15)

11 (28)

5 (15)

2 (2)

0

0

1 (3)

 Pneumonia

22 (16)

20 (15)

5 (13)

4 (12)

15 (11)

14 (10)

2 (5)

3 (9)

 Asthenia

15 (11)

19 (14)

4 (10)

9 (27)

1 (1)

3 (2)

0

1 (3)

 Hypertension

15 (11)

5 (4)

4 (10)

1 (3)

9 (7)

1 (1)

2 (5)

0

 Decreased appetite

14 (10)

8 (6)

10 (25)

1 (3)

0

1 (1)

1 (3)

0

 Spinal pain

4 (3)

3 (2)

2 (5)

0

1 (1)

0

2 (5)

0

 Gastroenteritis

2 (2)

3 (2)

2 (5)

1 (3)

0

2 (2)

2 (5)

1 (3)

 Squamous cell carcinoma of the skin

0

0

2 (5)

0

0

0

2 (5)

0

  1. TEAE treatment-emergent adverse event, D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone
  2. aPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality